Bank Hapoalim BM reduced its position in shares of Opko Health, Inc. (NASDAQ:OPK) by 39.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,335 shares of the biotechnology company’s stock after selling 46,990 shares during the period. Bank Hapoalim BM’s holdings in Opko Health were worth $483,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Financial Architects Inc raised its stake in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares in the last quarter. Blair William & Co. IL bought a new position in Opko Health in the second quarter worth about $112,000. Timber Hill LLC bought a new position in Opko Health in the first quarter worth about $114,000. Engineers Gate Manager LP bought a new position in Opko Health in the second quarter worth about $117,000. Finally, IFC Holdings Incorporated FL raised its stake in Opko Health by 16.5% in the second quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the biotechnology company’s stock worth $119,000 after buying an additional 2,525 shares in the last quarter. Institutional investors own 22.46% of the company’s stock.
Shares of Opko Health, Inc. (NASDAQ:OPK) traded up 0.84% during trading on Monday, hitting $6.02. 1,258,470 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $6.21 and a 200-day moving average price of $6.88. The stock’s market cap is $3.37 billion. Opko Health, Inc. has a one year low of $5.85 and a one year high of $12.15.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm’s quarterly revenue was down 12.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.02 EPS. Equities research analysts expect that Opko Health, Inc. will post ($0.19) EPS for the current fiscal year.
A number of equities analysts recently issued reports on the stock. Jefferies Group LLC reissued a “hold” rating and issued a $6.50 price target (down from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $12.00 to $7.00 in a research note on Thursday. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Barrington Research increased their price target on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.36.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 260,000 shares of the stock in a transaction dated Thursday, September 14th. The stock was purchased at an average price of $5.98 per share, with a total value of $1,554,800.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,352,326.98. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 1,182,800 shares of company stock valued at $7,372,211. 40.19% of the stock is owned by corporate insiders.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.